Day: March 24, 2022

March 24th2021 Annual Report and Investor Conference Call Announcement Welltec® will disclose its 2021 Annual Report and will discuss the results during an investor conference call to be held Thursday, March 31st 2022 at 5 pm CEST. The conference call will be available only for current and prospective bond holders, broker dealers and securities analysts and can be accessed by dialing in a few minutes before the start and informing the operator that you would like to participate in Welltec’s investor conference call. Relevant dial-in details and conference ID can be obtained by contacting Mads Brixtofte Rasmussen mbrasmussen@welltec.com and registering for the call. Registration will not be possible once the investor conference has started. The 2021 Annual Report will be made available in the “Investor Room” on Welltec’s website at http://www.welltec.com/investors. For...

HANGZHOU, China, March 24, 2022 (GLOBE NEWSWIRE) — UTStarcom (“UT” or the “Company”) (NASDAQ: UTSI), a global telecommunications infrastructure provider, today reported its unaudited financial results for the six months and full year ended December 31, 2021, and provided a business update. Business UpdateProgress in the development of Network Operating System (NOS) Software. In H2 2021, UTStarcom continued working with its customer China Unicom Research Institute on the cooperative development and field testing of a disaggregated networking solution for 5G transport networks. China Unicom Research Institute is a wholly owned subsidiary of China Unicom, one of the major mobile network operators (“MNO”) in China. The Company successfully finished interoperability testing with several 3rd party vendors and passed field trials on...

BEIJING, March 24, 2022 (GLOBE NEWSWIRE) — Kingsoft Cloud Holdings Limited (“Kingsoft Cloud” or the “Company”) (NASDAQ: KC), a leading independent cloud service provider in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2021. Mr. Yulin Wang, Chief Executive Officer of Kingsoft Cloud, commented, “Our total revenues reached RMB2.66 billion in the fourth quarter, representing a strong growth of 38% year-over-year. Revenues from public cloud services were RMB1.53 billion, which were negatively impacted by a sector-wide demand slowdown from the China internet space. To adapt to this market headwind, we conducted a timely strategic review of our businesses, proactively initiated down-sizing of our CDN services and focusing on non-CDN services (i.e. computing, storage and...

– Revenue for Fiscal 2022 Increased 21.3% to $1.7 billion – – Record Fiscal 2022 GAAP EPS of $2.92 and Adjusted EPS of $2.98, an increase of 239.5% and 173.4%, respectively – WEST FARGO, N.D., March 24, 2022 (GLOBE NEWSWIRE) — Titan Machinery Inc. (Nasdaq: TITN), a leading network of full-service agricultural and construction equipment stores, today reported financial results for the fiscal fourth quarter and full year ended January 31, 2022. David Meyer, Titan Machinery’s Chairman and Chief Executive Officer, stated, “Fiscal 2022 was an exceptional year for Titan Machinery where we delivered record earnings through sound management of our dealership network. This was the product of a tremendous effort by our team, whose unwavering focus provided the fuel to generate these record results. At the segment...

–Oral presentation on EDP1815 Phase 2 data in psoriasis accepted in late-breaking abstract session at AAD on Saturday, March 26, 2022 ––Positive data reported on faster release capsule––Phase 2 data from EDP1815 in atopic dermatitis on-track for 1H 2023 readout––Management to host conference call at 8:30 a.m. ET– CAMBRIDGE, Mass., March 24, 2022 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today reported financial results and business highlights for the fourth quarter and full year 2021. “We heard from Dr. Bruce Strober and Dr. Daniel Roling at our recent KOL event, that Evelo’s Phase 2 clinical data supports the potential use of EDP1815 in almost all patients, including the...